Page last updated: 2024-11-06

clevudine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Clevudine is a nucleoside analogue with antiviral activity against hepatitis B virus (HBV). It is a prodrug that is converted to its active form, clevudine triphosphate, inside cells. Clevudine triphosphate acts as a competitive inhibitor of HBV DNA polymerase, thereby inhibiting viral replication. The compound exhibits a favorable safety profile and has been investigated for the treatment of chronic HBV infection. Research on clevudine explores its efficacy, pharmacokinetic properties, potential for combination therapy, and long-term effects.'

Cross-References

ID SourceID
PubMed CID72327
CHEMBL ID475717
SCHEMBL ID139783
MeSH IDM0107362

Synonyms (44)

Synonym
nsc-678516
fm-ara-u
1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione
2'-fluoro-5-methyl-.beta.-d-arabinofuranosyluracil
2'-fluoro-5-methylarabinosyluracil
69256-17-3
2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-2-fluoro-.beta.-d-arabinofuranosyl)-5-methyl-
fmau
2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-methyl-
2'-fluoro-5-methyl-1-beta-d-arabinofuranosyluracil ,
1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-methyluracil
uracil, 1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-methyl-
1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
j61.760a ,
CHEMBL475717 ,
d-fmau
5-methyl-2'-fluoroarauracil
unii-37f7d05anb
nsc 678516
37f7d05anb ,
bdbm50367487
1-(2-deoxy-2-fluoro-b-d-arabinofuranosyl)-5-methyluracil
SCHEMBL139783
tox21_113880
dtxsid2057659 ,
NCGC00253767-01
dtxcid3031448
cas-163252-36-6
GBBJCSTXCAQSSJ-JVZYCSMKSA-N
1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)thymine
1-((2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1h,3h)-dione
mfcd00870799
AS-74549
1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
2'-fluoro-5-methyl-1-.beta.-d-arabinofuranosyluracil
1-(2-fluoro-2-deoxy-.beta.-d-arabinofuranosyl)thymine
C76189
A855627
1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione;1-(2-deoxy-2-fluoro-b-d-arabinofuranosyl)-5-methyluracil
EN300-7493207
2??-deoxy-2??-fluoro-5-methyl-beta-d-arabinouridine
AKOS016844133
Z2681892043
BP-58601

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.66820.006038.004119,952.5996AID1159521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine kinase, cytosolicHomo sapiens (human)Ki0.79000.09001.52137.0000AID210534; AID210537
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine kinase, cytosolicHomo sapiens (human)Km60.00000.29002.27675.0000AID210540
Thymidylate synthaseMus musculus (house mouse)ID501,000.00000.03500.03500.0350AID212649
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
nucleobase-containing compound metabolic processThymidine kinase, cytosolicHomo sapiens (human)
deoxyribonucleoside monophosphate biosynthetic processThymidine kinase, cytosolicHomo sapiens (human)
thymidine metabolic processThymidine kinase, cytosolicHomo sapiens (human)
thymidine biosynthetic processThymidine kinase, cytosolicHomo sapiens (human)
protein homotetramerizationThymidine kinase, cytosolicHomo sapiens (human)
DNA synthesis involved in mitotic DNA replicationThymidine kinase, cytosolicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
thymidine kinase activityThymidine kinase, cytosolicHomo sapiens (human)
protein bindingThymidine kinase, cytosolicHomo sapiens (human)
ATP bindingThymidine kinase, cytosolicHomo sapiens (human)
zinc ion bindingThymidine kinase, cytosolicHomo sapiens (human)
identical protein bindingThymidine kinase, cytosolicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
nucleusThymidine kinase, cytosolicHomo sapiens (human)
cytosolThymidine kinase, cytosolicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (83)

Assay IDTitleYearJournalArticle
AID73995Compound (5%) was evaluated for its effect on (no. of areas = 3) mean area under lesion score-day curve in HSV-1 cutaneous infection of guinea pig; expressed as mean area under lesion score-day curve1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent.
AID87995Antiviral activity against herpes simplex type-2 expressed as ED901985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID46754The growth inhibition activity for the compound was evaluated in CEM cells.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents.
AID86208Proliferation of Hep-2 cells by propagation on day 4 by measuring optical density (absorbance) at 30 ug/mL1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID85711Effective dose required for antiherpes activity against HSV-1(F) strain1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID217422Cytotoxic effect on Vero cells was determined in mock infected cell monolayers incubated with the compound for 48 hr at 37 degree celsius.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Fluoro carbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluoro carbocyclic pyrimidine nucleosides including carbocyclic 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-methyluracil and carbocyclic 1-(2-deoxy-2-fluoro-beta-D-arabinofu
AID99360In vitro inhibitory activity against L1212/0 cell line1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID217573Compound was tested for antiviral activity against Herpes simplex virus-1 (Strain F) in vero cells by plaque reduction assay.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Nucleosides. 136. Synthesis and antiviral effects of several 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-alkyluracils. Some structure-activity relationships.
AID83146Antiviral activity against VZV (Ellen) in human lung fibroblast (HLF-1) cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID102832Inhibition of growth of normal human lymphocytic cells1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Nucleosides. 123. Synthesis of antiviral nucleosides: 5-substituted 1-(2-deoxy-2-halogeno-beta-D-arabinofuranosyl)cytosines and -uracils. Some structure-activity relationships.
AID3013The growth inhibition activity for the compound was evaluated in 2.2.15 cells.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents.
AID154307In vitro inhibitory activity against P815/ara-C cell line1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID1123146Cytotoxicity against mouse P815 cells assessed as growth inhibition after 96 hrs1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.
AID86853Effective concentration against hepatitis B virus2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Rapid enantiomeric quantification of an antiviral nucleoside agent (D,L-FMAU, 2'-fluoro-5-methyl-beta,D,L-arabinofurano-syluracil) by mass spectrometry.
AID217888Antiviral activity against HSV-1 (Brand) in Vero cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID218068Compound was evaluated for cellular toxicity performed on Vero cells measured as 50% tissue culture inhibitory dose after 72 hr post exposure1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent.
AID217574Compound was tested for antiviral activity against Herpes simplex virus-2 (Strain G) in vero cells by plaque reduction assay.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Nucleosides. 136. Synthesis and antiviral effects of several 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-alkyluracils. Some structure-activity relationships.
AID86216Antiviral activity against HSV-2 (K979) in human epithelial (Hep-2) cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID217755Compound was evaluated for antiviral activity against Herpes simplex virus (HSV) -2 (MS) in Vero cell cultures1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent.
AID86034Effective concentration required to inhibit replication of strain F of HSV-1 by 90%1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogues of 2'-fluoroarabinosylpyrimidine nucleosides.
AID217419Proliferation of Vero cells by propagation on day 4 by measuring optical density (absorbance) at 100 ug/mL1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID73996Compound (5%) was evaluated for its effect on (no. of areas = 3) time to start healing in HSV-1 cutaneous infection of guinea pig; expressed as time to start healing1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent.
AID217889Antiviral activity against HSV-2 (K979) in Vero cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID3014Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents.
AID217754Compound was evaluated for antiviral activity against Herpes simplex virus (HSV) -1 (BW) in Vero cell cultures1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent.
AID210537Compound was evaluated for Kinetic constant for viral thymidine kinase of Herpes simplex virus (HSV) -21987Journal of medicinal chemistry, May, Volume: 30, Issue:5
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent.
AID217596Compound was tested for antiviral activity against Herpes simplex virus-2 (Strain G) in vero cells by plaque reduction assay.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Nucleosides. 136. Synthesis and antiviral effects of several 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-alkyluracils. Some structure-activity relationships.
AID217595Compound was tested for antiviral activity against Herpes simplex virus-1 (Strain F) in vero cells by plaque reduction assay.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Nucleosides. 136. Synthesis and antiviral effects of several 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-alkyluracils. Some structure-activity relationships.
AID86032Effective concentration required to inhibit replication of strain F of HSV-1 by 50%1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogues of 2'-fluoroarabinosylpyrimidine nucleosides.
AID235255Theuraptic Index: ratio of ID 50 / ED 90 of compound against HSV 11986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Nucleosides. 136. Synthesis and antiviral effects of several 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-alkyluracils. Some structure-activity relationships.
AID84941Effective concentration required to inhibit replication of strain G of HSV-2 by 50%1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogues of 2'-fluoroarabinosylpyrimidine nucleosides.
AID84937Antiherpetic activity against HSV-21983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Nucleosides. 123. Synthesis of antiviral nucleosides: 5-substituted 1-(2-deoxy-2-halogeno-beta-D-arabinofuranosyl)cytosines and -uracils. Some structure-activity relationships.
AID3004Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents.
AID217750Antiherpes activity was measured in a plaque reduction assay in Vero cells, against HSV-2 strain 186.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Fluoro carbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluoro carbocyclic pyrimidine nucleosides including carbocyclic 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-methyluracil and carbocyclic 1-(2-deoxy-2-fluoro-beta-D-arabinofu
AID84943Effective concentration required to inhibit replication of strain G of HSV-2 by 90%1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogues of 2'-fluoroarabinosylpyrimidine nucleosides.
AID91304In vitro inhibitory activity against Herpes simplex virus-1(HSV-2) was determined in human foreskin fibroblasts1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Nucleosides. 146. 1-Methyl-5-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil, the C-nucleoside isostere of the potent antiviral agent 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)thymine (FMAU). Studies directed toward the synthesis of 2'-deoxy-2'-substit
AID392509Antiviral activity against Hepatitis B virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID87993Effect on thymidine kinase in the herpes simplex type-2 infected cells1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID91305In vitro inhibitory activity against Varicella zoster virus(VZV) was determined in human foreskin fibroblasts1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Nucleosides. 146. 1-Methyl-5-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil, the C-nucleoside isostere of the potent antiviral agent 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)thymine (FMAU). Studies directed toward the synthesis of 2'-deoxy-2'-substit
AID81489Inhibition of human promyelocytic leukemic cell (HL-60) trypan blue exclusion assay1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Fluorinated sugar analogues of potential anti-HIV-1 nucleosides.
AID86215Antiviral activity against HSV-1 (Brand) in human epithelial (Hep-2) cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID82317Growth inhibition against HL-60 after 48 hours incubation period1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID1123148Antiviral activity against HSV1 2931 infected in African green monkey Vero cells assessed as inhibition of virus replication at 1 ug/ml after 24 hrs relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.
AID82323The compound was tested for [3H]TdR incorporation into DNA in HL-60 cells1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID87844Antiviral activity against herpes simplex type-1 expressed as ED901985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID87842Effect on thymidine kinase in the herpes simplex type-1 infected cells1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID217421Proliferation of Vero cells by propagation on day 4 by measuring optical density (absorbance) at 330 ug/mL1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID91303In vitro inhibitory activity against Herpes simplex virus-1(HSV-1) was determined in human foreskin fibroblasts1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Nucleosides. 146. 1-Methyl-5-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil, the C-nucleoside isostere of the potent antiviral agent 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)thymine (FMAU). Studies directed toward the synthesis of 2'-deoxy-2'-substit
AID86207Proliferation of Hep-2 cells by propagation on day 4 by measuring optical density (absorbance) at 100 ug/mL1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID217756Compound was tested for cytotoxic activity against rapidly dividing Vero cells.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Nucleosides. 136. Synthesis and antiviral effects of several 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-alkyluracils. Some structure-activity relationships.
AID1123153Antiviral activity against HSV1 2931 infected in African green monkey Vero cells assessed as inhibition of virus replication at 0.1 ug/ml after 24 hrs relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.
AID82316Growth inhibition against HL-60 after 24 hours incubation period1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID156700Antiviral activity against HSV-1 (KOS) in Primary Rabbit Kidney (PRK) cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID81488Inhibition of human promyelocytic leukemic cell (HL-60) by XXT-microculture tetrazolium assay1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Fluorinated sugar analogues of potential anti-HIV-1 nucleosides.
AID212649The compound was tested for inhibition of thymidylate synthase (TS) in L1210 cells1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID210534Compound was evaluated for Kinetic constant for viral thymidine kinase of Herpes simplex virus (HSV) -11987Journal of medicinal chemistry, May, Volume: 30, Issue:5
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent.
AID78750Anti-HIV activity in H9 cell line; Not active1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Fluorinated sugar analogues of potential anti-HIV-1 nucleosides.
AID235593Ratio of ID50/ID90 in HSV-1 infected cells1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID218067Compound was evaluated for cellular toxicity performed on Vero cells measured as 50% tissue culture inhibitory dose after 120 hr post exposure1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent.
AID82318Growth inhibition against HL-60 after 72 hours incubation period1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID84759Effective dose required for antiherpes activity against HSV-2(G) strain1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID156701Antiviral activity against HSV-2 (G) in Primary Rabbit Kidney (PRK) cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID87183Compound (5%) was evaluated for its effect on (no. of areas = 3)mean peak lesion score in HSV-1 cutaneous infection of guinea pig; expressed as mean peak lesion score1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent.
AID210540Compound was evaluated for Kinetic constant for cellular thymidine kinase in Vero cells1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent.
AID235596Ratio of ID50/ID90 in HSV-2 infected cells1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID216191Compound was evaluated for cytotoxicity in rapidly dividing Vero cells1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogues of 2'-fluoroarabinosylpyrimidine nucleosides.
AID217420Proliferation of Vero cells by propagation on day 4 by measuring optical density (absorbance) at 30 ug/mL1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID87843Antiviral activity against herpes simplex type-1 expressed as ED501985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID1123152Antiviral activity against HSV1 2931 infected in African green monkey Vero cells assessed as inhibition of virus replication at 0.01 ug/ml after 24 hrs relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.
AID86209Proliferation of Hep-2 cells by propagation on day 4 by measuring optical density (absorbance) at 330 ug/mL1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID1123150Antiviral activity against HSV1 2931 infected in African green monkey Vero cells assessed as inhibition of virus replication at 100 ug/ml after 24 hrs relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.
AID235256Theuraptic Index: ratio of ID 50 / ED 90 of compound against HSV 21986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Nucleosides. 136. Synthesis and antiviral effects of several 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-alkyluracils. Some structure-activity relationships.
AID1123149Antiviral activity against HSV1 2931 infected in African green monkey Vero cells assessed as inhibition of virus replication at 10 ug/ml after 24 hrs relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.
AID217748Antiherpes activity was measured in a plaque reduction assay in Vero cells, against HSV-1 strain KOS.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Fluoro carbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluoro carbocyclic pyrimidine nucleosides including carbocyclic 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-methyluracil and carbocyclic 1-(2-deoxy-2-fluoro-beta-D-arabinofu
AID218385Cytotoxic activity against vero cells was evaluated.1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID1123151Cytotoxicity against mouse L5178Y cells assessed as growth inhibition after 96 hrs1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.
AID154306In vitro inhibitory activity against P815/0 cell line1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID73997Compound (5%) was evaluated for its effect on (no. of areas = 3)maximum score in HSV-1 cutaneous infection of guinea pig; expressed as maximum score1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent.
AID86026Antiherpetic activity against HSV-11983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Nucleosides. 123. Synthesis of antiviral nucleosides: 5-substituted 1-(2-deoxy-2-halogeno-beta-D-arabinofuranosyl)cytosines and -uracils. Some structure-activity relationships.
AID87994Antiviral activity against herpes simplex type-2 expressed as ED501985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (60.00)18.7374
1990's3 (20.00)18.2507
2000's2 (13.33)29.6817
2010's1 (6.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.53 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index38.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (30)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pilot Feasibility Study of 18F-FMAU PET for Diagnosing and Characterizing Prostate Cancer [NCT02809690]Phase 118 participants (Actual)Interventional2016-09-12Terminated(stopped due to Slow accrual)
A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period [NCT01264094]Phase 4200 participants (Anticipated)Interventional2009-11-30Terminated(stopped due to Enrollment)
An Open Study to Evaluate the Efficacy, Safety and Sustained Effect of Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With Chronic Hepatitis B Associated Hepatocellular Carcinoma [NCT01263002]Phase 433 participants (Anticipated)Interventional2010-06-30Completed
A Multi-center, Randomized, Double-blind, Positive-control, Phase III Trial of the Efficacy and Safety of Clevudine [NCT01192854]Phase 3288 participants (Actual)Interventional2010-02-28Completed
ANRS HB 05 : A Randomized, Double Blind, Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepa [NCT00823342]Phase 3150 participants (Anticipated)Interventional2008-12-14Terminated(stopped due to safety aspects)
Novel Dynamic PET Kinetics and MRI Radiomics Analyses in Brain Tumors [NCT04752267]Early Phase 110 participants (Actual)Interventional2021-02-15Active, not recruiting
An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B [NCT01264354]Phase 460 participants (Anticipated)Interventional2010-03-31Completed
An Open Study to Evaluate the Efficacy, Safety and Sustained Effect of Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With Chronic Hepatitis B [NCT01264133]Phase 4200 participants (Anticipated)Interventional2009-09-30Terminated
A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis [NCT01264367]Phase 460 participants (Anticipated)Interventional2008-12-31Completed
A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients [NCT01266005]Phase 475 participants (Anticipated)Interventional2009-08-31Terminated
A Open Randomized Clinical Trial Comparing the Efficacy and Safety of Clevudine 30mg Versus Adefovir 10mg in Patients With LC-B [NCT00672867]Phase 3102 participants (Anticipated)Interventional2007-12-31Completed
A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function [NCT00641082]Phase 443 participants (Actual)Interventional2008-02-29Completed
A Multicenter, Randomized, Controlled Tial of Combination Therapy for Lamivudine-resistant Chronic Hepatitis B Patient: Comparing Clevudine Plus Adefovir With Lamivudine Plus Adefovir [NCT00798460]Phase 430 participants (Actual)Interventional2008-12-31Terminated(stopped due to could not enroll patients)
A Double Blind, Randomized, Placebo-controlled, Multi-center, Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Mild and Moderate COVID-19 [NCT04891302]Phase 2104 participants (Actual)Interventional2021-03-19Completed
A Double- Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 Mg QD and 50 Mg QD Doses in Patients Infected With Hepatitis B Virus [NCT00305019]Phase 2120 participants Interventional2002-07-31Terminated
A Randomized, Open-label, Three-sequence, Three-period, Three-treatment Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects [NCT01581242]Phase 142 participants (Anticipated)Interventional2012-04-30Completed
Phase lV Study to Evaluate the Safety and Effectiveness of Switching Treatment From Lamivudine to Clevudine in the Chronic Hepatitis B Patients With Suboptimal Virologic Response During Lamivudine Treatment [NCT00558493]Phase 4100 participants (Anticipated)Interventional2007-11-30Completed
A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Positive Chronic Hepatitis Due to Hepati [NCT00496002]Phase 30 participants Interventional2007-08-31Terminated(stopped due to The study was terminated in the interest of patient safety.)
A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepati [NCT00496158]Phase 30 participants Interventional2007-08-31Terminated(stopped due to The study was terminated in the interest of patient safety.)
A Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19 [NCT04347915]Phase 264 participants (Actual)Interventional2020-05-26Completed
A Phase lV Study to Evaluate the Long-term Safety and Efficacy of Clevudine in the Patients Chronically Infected With Hepatitis B Virus [NCT00558818]Phase 4150 participants (Anticipated)Interventional2007-06-30Completed
An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of Retreated Clevudine in Chronic Hepatitis B Patients Who Received Clevudine in L-FMAU-201 [NCT00362700]Phase 233 participants Interventional2003-07-31Terminated
An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of L-FMAU (Clevudine) in Chronic Hepatitis B Patients of L-FMAU-201 Placebo Group [NCT00313261]Phase 20 participants Interventional2003-06-30Terminated
Phase IV Study to Evaluate the Safety and Efficacy of Clevudine Compared With Clevudine and Vaccine in Patients Chronically Infected With HBV, HBeAg(+) [NCT00501124]Phase 470 participants (Anticipated)Interventional2007-05-31Completed
A Phase II, Randomized, Partially-Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of 12 Weeks of Treatment with Clevudine (10 mg, 30 mg or 50 mg QD) in Patients Infected with Hepatitis B Virus. [NCT00044135]Phase 230 participants Interventional2002-08-31Active, not recruiting
A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 mg QD in Patients Chronically Infected With Hepatitis B Virus [NCT00313287]Phase 3180 participants Interventional2003-06-30Terminated
A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine (L-FMAU) 30 mg QD in Patients With HBeAg Negative Chronic Hepatitis B [NCT00313274]Phase 380 participants Interventional2003-07-31Terminated
An Open-label, Phase III Clinical Trial to Evaluate the Safety and Antiviral Activity of Clevudine in Chronic Hepatitis B Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials [NCT00362505]Phase 30 participants Interventional2004-06-30Terminated
A Double-blinded and Randomised Study to Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30 mg qd Versus Lamivudine 100 mg qd for Chronic Hepatitis B Infection [NCT00362635]Phase 392 participants (Anticipated)Interventional2006-08-31Completed
Development of an In Vivo Cell Proliferation Marker for PET Assessment of Chemotherapeutic Response in Cancer [NCT01712815]12 participants (Actual)Interventional2013-11-22Terminated(stopped due to Insufficient accrual)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]